Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 95, Issue 1, 2016, Pages 505-516

  Chang, Joe Y ^a   Jabbour, Salma K ^b   De Ruysscher, Dirk ^c   Schild, Steven E ^d   Simone, Charles B ^e   Rengan, Ramesh ^f   Feigenberg, Steven ^g   Khan, Atif J ^b   Choi, Noah C ^h   Bradley, Jeffrey D ⁱ   Zhu, Xiaorong R ^a   Lomax, Antony J ^j   Hoppe, Bradford S ^k  

^a UNIVERSITY OF TEXAS   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c MAASTRO CLINIC   (Netherlands)

^d MAYO CLINIC   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^g UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j PAUL SCHERRER INSTITUTE   (Switzerland)

^k UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; BLOOD VESSELS; CLINICAL RESEARCH; COMPUTERIZED TOMOGRAPHY; COST EFFECTIVENESS; COST REDUCTION; DISEASES; DOSIMETRY; PHOTONS; PROTON BEAMS; RADIATION EFFECTS; RADIOTHERAPY;

FUTURE RESEARCH DIRECTIONS; INTENSITY-MODULATED; LARGE BLOOD VESSELS; LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCERS; NON SMALL CELL LUNG CANCER; PHYSICAL CHARACTERISTICS; TECHNOLOGY IMPROVEMENT; TRANSLATIONAL RESEARCH;

PROTON BEAM THERAPY;

ADVANCED CANCER; ARTICLE; BRACHIAL PLEXUS; CANCER MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; EARLY CANCER; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG VOLUME; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; ORGANS AT RISK; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON RADIATION; PROTON THERAPY; QUALITY CONTROL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC RADIOSURGERY; TREATMENT PLANNING; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; ECONOMICS; LUNG NEOPLASMS; MOVEMENT (PHYSIOLOGY); PATHOLOGY; PROCEDURES; RADIATION INJURIES; RADIATION RESPONSE; RADIATION SCATTERING; RADIOTHERAPY PLANNING SYSTEM;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CONSENSUS; HUMANS; LUNG NEOPLASMS; MOVEMENT; ORGAN SPARING TREATMENTS; ORGANS AT RISK; PROTON THERAPY; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SCATTERING, RADIATION; TUMOR BURDEN;

EID: 84963596225     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.01.036     Document Type: Review

References (70)

1. R. Timmerman, R. Paulus, J. Galvin, and et al. Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
2. S.M. Shirvani, J. Jiang, J.Y. Chang, and et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly JAMA Surg 149 2014 1244 1253
3. J.Y. Chang, S. Senan, M.A. Paul, and et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials Lancet Oncol 16 2015 630 637
4. J.D. Bradley, R. Paulus, R. Komaki, and et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study Lancet Oncol 16 2015 187 199
5. Chun SG, Hu C, Choy H, et al. Outcomes of intensity modulated and 3D-conformal radiotherapy for stage III non-small cell lung cancer in NRG oncology/RTOG 0617. Presented at: 16th World Conference on Lung Cancer. September 6-10, 2015; Denver, CO.
6. J.Y. Chang, X. Zhang, X. Wang, and et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 65 2006 1087 1096
7. T. Auberger, K. Seydl, T. Futschek, and et al. Photons or protons: Precision radiotherapy of lung cancer Strahlenther Onkol 183 2007 3 6
8. X. Zhang, Y. Li, X. Pan, and et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: A virtual clinical study Int J Radiat Oncol Biol Phys 77 2009 357 366
9. R. Mohan, J. Matney, J. Bluett, and et al. IMRT versus passively scattered proton therapy (PSPT) for locally advanced NSCLC: Impact of changing techniques and technologies over the course of a randomized trial [abstract] Int J Radiat Oncol Biol Phys 84 2012 S565 S566
10. J. Matney, P.C. Park, J. Bluett, and et al. Effects of respiratory motion on passively scattered proton therapy versus IMRT for stage III lung cancer: Are proton plans more sensitive to breathing motion? Int J Radiat Oncol Biol Phys 87 2013 576 582
11. S.P. Register, X. Zhang, R. Mohan, and et al. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 80 2011 1015 1022
12. F. Albertini, A. Bolsi, A.J. Lomax, and et al. Sensitivity of intensity modulated proton therapy plans to changes in patient weight Radiother Oncol 86 2008 187 194
13. M. Engelsman, E. Rietzel, and H.M. Kooy Four-dimensional proton treatment planning for lung tumors Int J Radiat Oncol Biol Phys 64 2006 1589 1595
14. J.Y. Chang, H. Li, X.R. Zhu, and et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies Int J Radiat Oncol Biol Phys 90 2014 809 818
15. B.S. Hoppe, S. Huh, S. Flampouri, and et al. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapy Radiother Oncol 97 2010 425 430
16. O.K. Macdonald, J.J. Kruse, J.M. Miller, and et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: A comparative dosimetric analysis Int J Radiat Oncol Biol Phys 75 2009 950 958
17. J. Welsh, A. Amini, K. Ciura, and et al. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer Med Dosim 38 2013 442 447
18. J. Seco, G. Gu, T. Marcelos, and et al. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer Int J Radiat Oncol Biol Phys 87 2013 188 194
19. L. Zhao, G.A. Sandison, J.B. Farr, and et al. Dosimetric impact of intrafraction motion for compensator-based proton therapy of lung cancer Phys Med Biol 53 2008 3343 3364
20. J.Y. Chang, L. Dong, H. Liu, and et al. Image-guided radiation therapy for non-small cell lung cancer J Thorac Oncol 3 2008 177 186
21. Z. Hui, X. Zhang, G. Starkschall, and et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer Int J Radiat Oncol Biol Phys 72 2008 1385 1395
22. E.J. Koay, D. Lege, R. Mohan, and et al. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer Int J Radiat Oncol Biol Phys 84 2012 1093 1100
23. Ho J, Li H, Zhang X, et al. Clinical outcome of intensity modulated proton therapy for NSCLC. Presented at: 57th Annual Meeting of the American Society for Radiation Oncology. October 18-21, 2015; San Antonio, TX.
24. J.Y. Chang Intensity-modulated radiotherapy, not 3D conformal, is the preferred technique for treating locally advanced lung cancer Semin Radiat Oncol 25 2015 110 116
25. D.A. Bush, J.D. Slater, R. Bonnet, and et al. Proton-beam radiotherapy for early-stage lung cancer Chest 116 1999 1313 1319
26. D.A. Bush, G. Cheek, S. Zaheer, and et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: Results of a 12-year experience at Loma Linda University Medical Center Int J Radiat Oncol Biol Phys 86 2013 964 968
27. Y. Shioyama, K. Tokuuye, T. Okumura, and et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 56 2003 7 13
28. K. Nihei, T. Ogino, S. Ishikura, and et al. High-dose proton beam therapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 65 2006 107 111
29. M. Hata, K. Tokuuye, K. Kagei, and et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study Int J Radiat Oncol Biol Phys 68 2007 786 793
30. H. Nakayama, S. Sugahara, M. Tokita, and et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba Int J Radiat Oncol Biol Phys 78 2010 467 471
31. J.Y. Chang, R. Komaki, H.Y. Wen, and et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer Int J Radiat Oncol Biol Phys 80 2011 1350 1357
32. K.D. Westover, J. Seco, J.A. Adams, and et al. Proton SBRT for medically inoperable stage I NSCLC J Thorac Oncol 7 2012 1021 1025
33. A. Kanemoto, T. Okumura, H. Ishikawa, and et al. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non-small-cell lung cancer Clin Lung Cancer 15 2014 e7 e12
34. H. Iwata, M. Murakami, Y. Demizu, and et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer Cancer 116 2010 2476 2485
35. J.P. Grutters, A.G. Kessels, M. Pijls-Johannesma, and et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis Radiother Oncol 95 2010 32 40
36. D. Georg, M. Hillbrand, M. Stock, and et al. Can protons improve SBRT for lung lesions? Dosimetric considerations Radiother Oncol 88 2008 368 375
37. N. Kadoya, Y. Obata, T. Kato, and et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 79 2011 1225 1231
38. A. Peeters, J. Grutters, M. Pijls-Johannesma, and et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons, and photons Radiother Oncol 95 2010 45 53
39. C.F. Serago, A.F. Thornton, M.M. Urie, and et al. Comparison of proton and x-ray conformal dose distributions for radiosurgery applications Med Phys 22 1995 2111 2116
40. R. Timmerman, R. McGarry, C. Yiannoutsos, and et al. Excessive toxicity when treating central tumors in a phase II study of SBRT for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
41. Bezjak A, Paulus R, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiotherapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Presented at: 57th Annual Meeting of the American Society for Radiation Oncology. October 18-21, 2015; San Antonio, TX.
42. J.Y. Chang, P.A. Balter, L. Dong, and et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer Int J Radiat Oncol Biol Phys 72 2008 967 971
43. W. Shi, J.R.C. Nichols, S. Flampouri, and et al. Proton-based chemoradiation for synchronous bilateral non-small-cell lung cancers: A case report Thorac Cancer 4 2013 198 202
44. C. Schaake-Koning, W. van den Bogaert, O. Dalesio, and et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 326 1992 524 530
45. K. Furuse, M. Fukuoka, M. Kawahara, and et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
46. W.J. Curran Jr., R. Paulus, C.J. Langer, and et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410 J Natl Cancer Inst 103 2011 1452 1460
47. R.C. Nichols, S.N. Huh, R.H. Henderson, and et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: A dosimetric study Clin Lung Cancer 12 2011 252 257
48. J.Y. Chang, R. Komaki, C. Lu, and et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer Cancer 117 2011 4707 4713
49. B.S. Hoppe Phase II trial of concurrent chemotherapy and proton therapy for stage 3 NSCLC Int J Particle Ther 2 2014 58
50. Y. Oshiro, T. Okumura, K. Kurishima, and et al. High-dose concurrent chemo-proton therapy for stage III NSCLC: Preliminary results of a phase II study J Radiat Res 55 2014 959 965
51. Q.N. Nguyen, N.B. Ly, R. Komaki, and et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer Radiother Oncol 115 2015 367 372
52. S. Sejpal, R. Komaki, A. Tsao, and et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer Cancer 117 2011 3004 3013
53. D.R. Gomez, M. Gillin, Z. Liao, and et al. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer Int J Radiat Oncol Biol Phys 86 2013 665 670
54. S. McAvoy, K. Ciura, C. Wei, and et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: Predictors of high-grade toxicity and survival outcomes Int J Radiat Oncol Biol Phys 90 2014 819 827
55. S.A. McAvoy, K.T. Ciura, J.M. Rineer, and et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer Radiother Oncol 109 2013 38 44
56. M.S. Rutenberg, R.C. Nichols, S. Flampouri, and et al. Proton radiotherapy in reirradiation for recurrent NSCLC Int J Particle Ther 1 2014 774 775
57. R.L. Foote, S.L. Stafford, I.A. Petersen, and et al. The clinical case for proton beam therapy Radiat Oncol 7 2012 174
58. B.L. Ramaekers, M.A. Joore, B. Lueza, and et al. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients J Thorac Oncol 8 2013 1295 1307
59. L. Kutikova, L. Bowman, S. Chang, and et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States Lung Cancer 50 2005 143 154
60. M. Pompen, M. Gok, A. Novak, and et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in the Netherlands Lung Cancer 64 2009 110 116
61. L. Barbera, H. Walker, F. Foroudi, and et al. Estimating the benefit and cost of radiotherapy for lung cancer Int J Technol Assess Health Care 20 2004 545 551
62. C. Chouaid, K. Atsou, G. Hejblum, and et al. Economics of treatments for non-small cell lung cancer Pharmacoeconomics 27 2009 113 125
63. Y. Lievens, K. Kesteloot, and W. Van den Bogaert Chart in lung cancer: Economic evaluation and incentives for implementation Radiother Oncol 75 2005 171 178
64. A. Vergnenegre, C. Combescure, P. Fournel, and et al. Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01) Ann Oncol 17 2006 1269 1274
65. C.H. Park, M. Bonomi, J. Cesaretti, and et al. Effect of radiotherapy planning complexity on survival of elderly patients with unresected localized lung cancer Int J Radiat Oncol Biol Phys 81 2011 706 711
66. S.H. Lin, L. Wang, B. Myles, and et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer Int J Radiat Oncol Biol Phys 84 2012 1078 1085
67. M. Goitein, and M. Jermann The relative costs of proton and x-ray radiation therapy Clin Oncol 15 2003 S37 S50
68. Y. Lievens, and W. Van den Bogaert Proton beam therapy: Too expensive to become true? Radiother Oncol 75 2005 131 133
69. J.P. Grutters, K.R. Abrams, D. de Ruysscher, and et al. When to wait for more evidence? Real options analysis in proton therapy Oncologist 16 2011 1752 1761
70. J.P. Grutters, M. Sculpher, A.H. Briggs, and et al. Acknowledging patient heterogeneity in economic evaluation: A systematic literature review Pharmacoeconomics 31 2013 111 123